Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

ECCO: Triple Regimen "Very Active" in Advanced Ovarian Cancer By Michael Smith COPENHAGEN, DENMARK -- September 22, 2003 -- The 3-drug combination of docetaxel, epirubicin, and cisplatin is very active in advanced ovarian cancer, a Dutch researcher said here September 22nd at ECCO 12: The European Cancer Conference. At the same time, the toxicity of the combination -- which was, as expected, high -- was acceptable, said Roy Lalisang, MD, University Hospital Maastricht, Maastricht, The Netherlands. The study adds more evidence that anthracyclines such as epirubicin have a role to play in treating ovarian cancer, he said. In the study, 87 women with epithelial ovarian cancer first underwent laparotomy to reduce the tumour size, and then were started on the triple-drug combination for at least 6 cycles to a maximum of 9 cycles on a 3-week schedule. All the women were supplemented with the granulocyte colony stimulating factor lenograstim, in an attempt to avoid the neutropaenia associated with docetaxel. Median overall survival was 49 months, which Dr. Lalisang said was comparable to standard regimens. At the same time, the median disease-free survival was 23 months, he said. The regimen produced a clinically complete response in 70% of the women. A second-look laparotomy was performed on 48 patients, which showed a histologically complete response in 43%. As expected, the regimen produced a suite of grade 3 and 4 toxicities, but the most common was neutropaenia, seen in 62% of women. On the other hand, Dr. Lalisang said, only 9% of he women had febrile neutropaenia. "We knew that [docetaxel and epirubicin] would give high numbers of neutropaenia and even febrile neutropaenia," he said, which prompted the investigators to add the lenograstim. In the long run, he said, it is possible that this triple combination -- or one like it -- "may be the new standard" of treatment for advanced ovarian cancer, but more research on the role of anthracyclines is needed. [Study title: A Phase II Study of Docetaxel, Epirubicin, and Cisplatin with G-CSF (Lenograstim) Support in Patients with Advanced Ovarian Cancer. Abstract 168] E-mail this page to a friend or colleague! To print, use this version